Brief: Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
23/09/2024 14:16
Sept 23 (Reuters) - Elevation Oncology Inc ELEV.O :
* ELEVATION ONCOLOGY RECEIVES FAST TRACK DESIGNATION FROM
THE FDA
FOR EO-3021 FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR
METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER
EXPRESSING CLAUDIN 18.2
* ELEVATION ONCOLOGY: LOOK TO ADVANCING THROUGH MONOTHERAPY
DOSE
EXPANSION, REPORTING MORE DATA FROM ONGOING TRIAL IN H1 2025
Source text for Eikon: ID:nPn8DHf18a
Further company coverage: ELEV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elevation Oncology
See all newsBrief: Elevation Oncology Terminates License Agreement With CSPC Megalith Biopharmaceutical
U.S. RESEARCH ROUNDUP- Crane, Ryder System, Terex
Brief: Elevation Oncology Says Concentra To Buy Elevation Oncology For $0.36 Per Share Plus CVR
Elevation Oncology Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Elevation Oncology Inc - To Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022 - SEC Filing